| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pneumonectomy | 54 | 2024 | 206 | 13.710 |
Why?
|
| Lung Neoplasms | 70 | 2024 | 2347 | 6.990 |
Why?
|
| Thoracic Surgery, Video-Assisted | 8 | 2021 | 30 | 3.190 |
Why?
|
| Thoracic Surgical Procedures | 7 | 2024 | 55 | 3.190 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 33 | 2023 | 1114 | 3.130 |
Why?
|
| Risk Assessment | 25 | 2024 | 2290 | 3.030 |
Why?
|
| Esophageal Neoplasms | 24 | 2021 | 332 | 2.950 |
Why?
|
| Postoperative Complications | 33 | 2024 | 2275 | 2.610 |
Why?
|
| Esophagectomy | 14 | 2021 | 92 | 2.430 |
Why?
|
| Thoracic Surgery | 5 | 2024 | 44 | 2.060 |
Why?
|
| Frailty | 5 | 2024 | 76 | 1.940 |
Why?
|
| Surgeons | 5 | 2023 | 247 | 1.780 |
Why?
|
| Decision Making | 5 | 2019 | 665 | 1.640 |
Why?
|
| Barrett Esophagus | 12 | 2015 | 93 | 1.630 |
Why?
|
| Pulmonary Diffusing Capacity | 10 | 2015 | 24 | 1.620 |
Why?
|
| Lung Diseases | 9 | 2015 | 269 | 1.540 |
Why?
|
| Esophagoscopy | 6 | 2015 | 90 | 1.530 |
Why?
|
| Adenocarcinoma | 22 | 2020 | 1194 | 1.480 |
Why?
|
| Humans | 178 | 2024 | 89063 | 1.470 |
Why?
|
| Clinical Competence | 6 | 2020 | 780 | 1.440 |
Why?
|
| Simulation Training | 3 | 2021 | 97 | 1.370 |
Why?
|
| Physicians | 4 | 2019 | 689 | 1.280 |
Why?
|
| Aged | 78 | 2024 | 19077 | 1.210 |
Why?
|
| Male | 107 | 2024 | 42251 | 1.170 |
Why?
|
| Middle Aged | 84 | 2024 | 25863 | 1.160 |
Why?
|
| Lymphatic System | 10 | 2000 | 55 | 1.140 |
Why?
|
| Neoplasm Staging | 24 | 2023 | 2001 | 1.110 |
Why?
|
| Female | 105 | 2024 | 46011 | 1.070 |
Why?
|
| Esophageal Diseases | 5 | 2019 | 27 | 1.070 |
Why?
|
| Retrospective Studies | 47 | 2024 | 9003 | 1.000 |
Why?
|
| Esophagus | 7 | 2015 | 106 | 0.990 |
Why?
|
| Esophageal Perforation | 5 | 2015 | 18 | 0.950 |
Why?
|
| Precancerous Conditions | 4 | 2015 | 200 | 0.950 |
Why?
|
| Cardiovascular Diseases | 4 | 2014 | 705 | 0.850 |
Why?
|
| Internship and Residency | 3 | 2022 | 1041 | 0.850 |
Why?
|
| Defibrillators, Implantable | 2 | 2022 | 142 | 0.840 |
Why?
|
| Channelopathies | 1 | 2022 | 4 | 0.830 |
Why?
|
| Hyperhidrosis | 1 | 2022 | 10 | 0.820 |
Why?
|
| Mediastinum | 3 | 2020 | 47 | 0.820 |
Why?
|
| Caustics | 1 | 2022 | 4 | 0.820 |
Why?
|
| Consensus | 5 | 2024 | 356 | 0.810 |
Why?
|
| Respiratory Function Tests | 6 | 2015 | 139 | 0.800 |
Why?
|
| Aged, 80 and over | 41 | 2021 | 6777 | 0.770 |
Why?
|
| Thoracotomy | 5 | 2015 | 64 | 0.770 |
Why?
|
| Treatment Outcome | 27 | 2022 | 8203 | 0.760 |
Why?
|
| Tachycardia, Ventricular | 1 | 2022 | 124 | 0.750 |
Why?
|
| Risk Factors | 19 | 2024 | 5466 | 0.740 |
Why?
|
| Physicians, Primary Care | 1 | 2022 | 105 | 0.730 |
Why?
|
| Body Composition | 2 | 2020 | 71 | 0.720 |
Why?
|
| Survival Rate | 20 | 2021 | 1889 | 0.690 |
Why?
|
| Thoracic Diseases | 2 | 2010 | 27 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 12 | 2016 | 1096 | 0.670 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2014 | 251 | 0.670 |
Why?
|
| Adult | 59 | 2024 | 26507 | 0.660 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2019 | 71 | 0.650 |
Why?
|
| Leadership | 2 | 2019 | 138 | 0.640 |
Why?
|
| Physicians, Women | 1 | 2018 | 56 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2019 | 599 | 0.600 |
Why?
|
| Biopsy | 4 | 2020 | 1182 | 0.600 |
Why?
|
| Follow-Up Studies | 17 | 2021 | 3657 | 0.600 |
Why?
|
| Clinical Decision-Making | 2 | 2024 | 280 | 0.590 |
Why?
|
| Gastroenterology | 1 | 2019 | 144 | 0.590 |
Why?
|
| Positron Emission Tomography Computed Tomography | 4 | 2022 | 93 | 0.580 |
Why?
|
| Sex Factors | 7 | 2019 | 1063 | 0.570 |
Why?
|
| Frail Elderly | 4 | 2024 | 82 | 0.560 |
Why?
|
| Incidence | 10 | 2019 | 1592 | 0.560 |
Why?
|
| Surgical Procedures, Operative | 2 | 2015 | 205 | 0.560 |
Why?
|
| Neoadjuvant Therapy | 5 | 2013 | 373 | 0.540 |
Why?
|
| Patients | 1 | 2017 | 102 | 0.540 |
Why?
|
| Prognosis | 19 | 2022 | 3773 | 0.530 |
Why?
|
| Esophagoplasty | 3 | 2015 | 10 | 0.530 |
Why?
|
| Delphi Technique | 4 | 2024 | 92 | 0.520 |
Why?
|
| Self Expandable Metallic Stents | 1 | 2015 | 7 | 0.520 |
Why?
|
| Specialties, Surgical | 1 | 2016 | 65 | 0.520 |
Why?
|
| Video-Assisted Surgery | 1 | 2015 | 6 | 0.520 |
Why?
|
| Mediastinal Diseases | 1 | 2015 | 22 | 0.520 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 1363 | 0.510 |
Why?
|
| Surgical Instruments | 1 | 2015 | 57 | 0.510 |
Why?
|
| Muscle Contraction | 8 | 2000 | 284 | 0.510 |
Why?
|
| Bronchi | 8 | 2017 | 229 | 0.500 |
Why?
|
| Mannosephosphates | 1 | 2014 | 2 | 0.500 |
Why?
|
| Geriatric Assessment | 1 | 2016 | 182 | 0.500 |
Why?
|
| Esophageal Stenosis | 3 | 2010 | 26 | 0.500 |
Why?
|
| Quality of Life | 4 | 2012 | 1662 | 0.490 |
Why?
|
| Drainage | 5 | 2024 | 162 | 0.490 |
Why?
|
| Tissue Adhesions | 1 | 2014 | 49 | 0.480 |
Why?
|
| Tendon Injuries | 1 | 2014 | 36 | 0.480 |
Why?
|
| Lung | 10 | 2022 | 1258 | 0.470 |
Why?
|
| Empyema, Pleural | 3 | 2021 | 10 | 0.470 |
Why?
|
| Wound Healing | 2 | 2014 | 359 | 0.470 |
Why?
|
| Muscle, Smooth | 7 | 2000 | 354 | 0.470 |
Why?
|
| Quality-Adjusted Life Years | 3 | 2011 | 142 | 0.460 |
Why?
|
| Learning Curve | 1 | 2013 | 19 | 0.460 |
Why?
|
| Vascular Neoplasms | 1 | 2014 | 21 | 0.460 |
Why?
|
| Postoperative Care | 7 | 2024 | 229 | 0.450 |
Why?
|
| Databases, Factual | 4 | 2024 | 850 | 0.450 |
Why?
|
| Pneumonia, Bacterial | 2 | 2012 | 29 | 0.450 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 105 | 0.440 |
Why?
|
| Perception | 1 | 2014 | 178 | 0.430 |
Why?
|
| Preoperative Care | 6 | 2009 | 396 | 0.430 |
Why?
|
| Gastric Dilatation | 1 | 2012 | 3 | 0.410 |
Why?
|
| Sympathectomy | 2 | 2022 | 17 | 0.410 |
Why?
|
| Thymectomy | 3 | 1999 | 31 | 0.410 |
Why?
|
| Pediatrics | 1 | 2016 | 352 | 0.410 |
Why?
|
| Patient Selection | 7 | 2016 | 682 | 0.410 |
Why?
|
| Forced Expiratory Volume | 8 | 2015 | 124 | 0.410 |
Why?
|
| Fundoplication | 4 | 1997 | 78 | 0.400 |
Why?
|
| Body Mass Index | 2 | 2014 | 771 | 0.400 |
Why?
|
| Thoracoscopy | 3 | 1999 | 23 | 0.400 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2023 | 103 | 0.390 |
Why?
|
| Myasthenia Gravis | 3 | 1999 | 83 | 0.390 |
Why?
|
| Spirometry | 7 | 2009 | 68 | 0.390 |
Why?
|
| Health Status Indicators | 1 | 2011 | 103 | 0.380 |
Why?
|
| Prospective Studies | 6 | 2020 | 4273 | 0.380 |
Why?
|
| Respiratory Tract Diseases | 1 | 2011 | 45 | 0.370 |
Why?
|
| Robotics | 1 | 2014 | 269 | 0.370 |
Why?
|
| Survival Analysis | 11 | 2017 | 1533 | 0.370 |
Why?
|
| Nomograms | 1 | 2010 | 29 | 0.370 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 1715 | 0.360 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 207 | 0.360 |
Why?
|
| Trachea | 7 | 1996 | 291 | 0.360 |
Why?
|
| Chylothorax | 2 | 2024 | 10 | 0.360 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 83 | 0.360 |
Why?
|
| Histamine | 4 | 1996 | 126 | 0.350 |
Why?
|
| Dilatation | 1 | 2010 | 48 | 0.350 |
Why?
|
| Lymph Nodes | 1 | 2014 | 548 | 0.350 |
Why?
|
| Postoperative Period | 3 | 2019 | 301 | 0.340 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2008 | 19 | 0.310 |
Why?
|
| Serum Albumin | 1 | 2008 | 127 | 0.310 |
Why?
|
| Pneumothorax | 2 | 2020 | 53 | 0.310 |
Why?
|
| Gastroesophageal Reflux | 5 | 1997 | 122 | 0.300 |
Why?
|
| Decision Support Techniques | 2 | 2012 | 167 | 0.300 |
Why?
|
| United States | 8 | 2021 | 6955 | 0.290 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 390 | 0.290 |
Why?
|
| History, 21st Century | 2 | 2019 | 180 | 0.290 |
Why?
|
| Stomach Diseases | 2 | 1997 | 19 | 0.290 |
Why?
|
| Biomarkers, Tumor | 4 | 2021 | 1543 | 0.290 |
Why?
|
| Catheterization | 4 | 1996 | 237 | 0.290 |
Why?
|
| Chicago | 6 | 2018 | 1423 | 0.290 |
Why?
|
| Obesity | 1 | 2014 | 966 | 0.290 |
Why?
|
| Exercise Test | 1 | 2008 | 165 | 0.290 |
Why?
|
| History, 20th Century | 2 | 2019 | 310 | 0.280 |
Why?
|
| Azygos Vein | 1 | 2006 | 4 | 0.280 |
Why?
|
| Video Recording | 2 | 2018 | 203 | 0.280 |
Why?
|
| Jejunal Diseases | 1 | 2006 | 10 | 0.280 |
Why?
|
| Computer Simulation | 2 | 2021 | 1097 | 0.280 |
Why?
|
| Mesothelioma | 2 | 2023 | 323 | 0.280 |
Why?
|
| Affect | 1 | 2009 | 387 | 0.270 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 296 | 0.270 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2006 | 31 | 0.270 |
Why?
|
| Probability | 4 | 2017 | 353 | 0.270 |
Why?
|
| Cohort Studies | 5 | 2022 | 2863 | 0.270 |
Why?
|
| Jejunum | 1 | 2006 | 80 | 0.270 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2010 | 485 | 0.270 |
Why?
|
| Stomach | 2 | 2006 | 111 | 0.270 |
Why?
|
| Enteral Nutrition | 1 | 2006 | 102 | 0.260 |
Why?
|
| Paxillin | 3 | 2013 | 59 | 0.260 |
Why?
|
| Neoplasms | 3 | 2016 | 3035 | 0.260 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 479 | 0.260 |
Why?
|
| Time Factors | 7 | 2021 | 5320 | 0.260 |
Why?
|
| Endothelium, Lymphatic | 2 | 1996 | 11 | 0.260 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2011 | 200 | 0.250 |
Why?
|
| MicroRNAs | 3 | 2015 | 551 | 0.250 |
Why?
|
| Pilot Projects | 6 | 2020 | 865 | 0.240 |
Why?
|
| Nitric Oxide | 3 | 1996 | 279 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 3 | 2020 | 461 | 0.240 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2017 | 103 | 0.240 |
Why?
|
| ROC Curve | 3 | 2024 | 781 | 0.240 |
Why?
|
| Elective Surgical Procedures | 3 | 2024 | 126 | 0.240 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 24 | 0.230 |
Why?
|
| Thoracostomy | 3 | 1999 | 10 | 0.230 |
Why?
|
| Illinois | 2 | 2018 | 472 | 0.230 |
Why?
|
| Endoscopy | 2 | 2014 | 348 | 0.220 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 13 | 2020 | 2552 | 0.220 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2022 | 197 | 0.220 |
Why?
|
| Esophageal Achalasia | 2 | 1996 | 60 | 0.220 |
Why?
|
| Pulmonary Edema | 1 | 2003 | 50 | 0.220 |
Why?
|
| Stomach Neoplasms | 2 | 2020 | 281 | 0.210 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 3 | 2012 | 257 | 0.210 |
Why?
|
| Lymph | 2 | 2000 | 13 | 0.210 |
Why?
|
| Jehovah's Witnesses | 1 | 2022 | 20 | 0.210 |
Why?
|
| Mesentery | 2 | 2000 | 45 | 0.210 |
Why?
|
| In Vitro Techniques | 7 | 2000 | 996 | 0.200 |
Why?
|
| Esophagogastric Junction | 3 | 2016 | 34 | 0.190 |
Why?
|
| Loss of Function Mutation | 1 | 2021 | 46 | 0.190 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2021 | 126 | 0.190 |
Why?
|
| Cost of Illness | 1 | 2022 | 147 | 0.190 |
Why?
|
| Sexism | 1 | 2021 | 53 | 0.190 |
Why?
|
| Deoxyribonucleases | 1 | 2021 | 29 | 0.190 |
Why?
|
| Combined Modality Therapy | 16 | 2013 | 1710 | 0.190 |
Why?
|
| Hand | 1 | 2022 | 133 | 0.190 |
Why?
|
| Exercise | 3 | 2024 | 322 | 0.190 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 121 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 112 | 0.190 |
Why?
|
| Eating | 1 | 2022 | 166 | 0.190 |
Why?
|
| Pleurodesis | 1 | 2020 | 8 | 0.190 |
Why?
|
| Risk | 4 | 2012 | 657 | 0.180 |
Why?
|
| Bronchial Neoplasms | 1 | 2000 | 9 | 0.180 |
Why?
|
| Pleural Effusion, Malignant | 1 | 2020 | 16 | 0.180 |
Why?
|
| Symptom Assessment | 1 | 2020 | 66 | 0.180 |
Why?
|
| Proportional Hazards Models | 4 | 2017 | 848 | 0.180 |
Why?
|
| Carcinoid Tumor | 1 | 2000 | 45 | 0.180 |
Why?
|
| Antibody Formation | 1 | 2020 | 171 | 0.180 |
Why?
|
| Frozen Sections | 1 | 2020 | 49 | 0.180 |
Why?
|
| Carcinoma | 5 | 2014 | 443 | 0.180 |
Why?
|
| Electronic Health Records | 1 | 2023 | 341 | 0.180 |
Why?
|
| International Agencies | 1 | 2019 | 35 | 0.180 |
Why?
|
| Adolescent | 13 | 2016 | 9237 | 0.180 |
Why?
|
| Neurofibroma | 1 | 1999 | 10 | 0.170 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 2612 | 0.170 |
Why?
|
| Medical Oncology | 2 | 2016 | 382 | 0.170 |
Why?
|
| New York | 1 | 2019 | 72 | 0.170 |
Why?
|
| Laminectomy | 1 | 1999 | 27 | 0.170 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2020 | 2657 | 0.170 |
Why?
|
| Outpatients | 1 | 2020 | 100 | 0.170 |
Why?
|
| Hospital Mortality | 2 | 2015 | 386 | 0.170 |
Why?
|
| Spinal Neoplasms | 1 | 1999 | 48 | 0.170 |
Why?
|
| Thoracic Vertebrae | 1 | 1999 | 51 | 0.170 |
Why?
|
| Length of Stay | 6 | 2021 | 732 | 0.170 |
Why?
|
| Reproducibility of Results | 2 | 2024 | 2752 | 0.170 |
Why?
|
| Societies, Medical | 3 | 2019 | 570 | 0.170 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2014 | 0.160 |
Why?
|
| Healthy Aging | 1 | 2019 | 10 | 0.160 |
Why?
|
| Age Factors | 4 | 2015 | 1867 | 0.160 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 309 | 0.160 |
Why?
|
| Swine | 6 | 1996 | 581 | 0.160 |
Why?
|
| Fibrinolytic Agents | 1 | 2021 | 214 | 0.160 |
Why?
|
| Tumor Burden | 2 | 2017 | 308 | 0.160 |
Why?
|
| Propensity Score | 1 | 2019 | 147 | 0.160 |
Why?
|
| Thoracic Neoplasms | 3 | 2011 | 64 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.160 |
Why?
|
| Bronchial Fistula | 2 | 1999 | 10 | 0.160 |
Why?
|
| Arteries | 1 | 2019 | 180 | 0.160 |
Why?
|
| Hospitals, University | 1 | 2018 | 195 | 0.160 |
Why?
|
| Epidemiologic Methods | 3 | 2010 | 60 | 0.160 |
Why?
|
| Pleural Diseases | 2 | 1999 | 14 | 0.150 |
Why?
|
| Lymphatic Metastasis | 4 | 2016 | 502 | 0.150 |
Why?
|
| Cisplatin | 8 | 2010 | 617 | 0.150 |
Why?
|
| Bias | 1 | 2018 | 131 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2008 | 1837 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 616 | 0.150 |
Why?
|
| Reward | 1 | 2019 | 188 | 0.140 |
Why?
|
| Disease Progression | 6 | 2012 | 1488 | 0.140 |
Why?
|
| Photochemotherapy | 1 | 1997 | 100 | 0.140 |
Why?
|
| Endosonography | 1 | 2017 | 98 | 0.140 |
Why?
|
| Pleura | 1 | 1996 | 31 | 0.140 |
Why?
|
| Receptors, Endothelin | 1 | 1996 | 12 | 0.140 |
Why?
|
| Endothelins | 1 | 1996 | 26 | 0.140 |
Why?
|
| Autoimmune Diseases | 1 | 1999 | 249 | 0.140 |
Why?
|
| Hand Strength | 1 | 2016 | 52 | 0.140 |
Why?
|
| Morbidity | 2 | 2013 | 149 | 0.140 |
Why?
|
| Gait | 1 | 2016 | 81 | 0.130 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2015 | 12 | 0.130 |
Why?
|
| Immunotherapy | 1 | 2021 | 669 | 0.130 |
Why?
|
| Necrosis | 2 | 2006 | 209 | 0.130 |
Why?
|
| Animals | 15 | 2015 | 27317 | 0.130 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2015 | 33 | 0.130 |
Why?
|
| Chemoradiotherapy | 3 | 2013 | 309 | 0.130 |
Why?
|
| omega-N-Methylarginine | 4 | 1996 | 17 | 0.130 |
Why?
|
| Tetralogy of Fallot | 1 | 2015 | 44 | 0.130 |
Why?
|
| Fatigue | 1 | 2016 | 179 | 0.130 |
Why?
|
| Heart Function Tests | 1 | 2015 | 33 | 0.130 |
Why?
|
| Child | 4 | 2022 | 7149 | 0.130 |
Why?
|
| Needs Assessment | 1 | 2016 | 157 | 0.130 |
Why?
|
| Education, Medical | 1 | 2018 | 243 | 0.130 |
Why?
|
| Hypertonic Solutions | 1 | 2014 | 17 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2015 | 49 | 0.120 |
Why?
|
| Self Report | 1 | 2016 | 295 | 0.120 |
Why?
|
| Anatomic Landmarks | 1 | 2015 | 30 | 0.120 |
Why?
|
| Weight Loss | 1 | 2016 | 225 | 0.120 |
Why?
|
| Thymus Gland | 1 | 1996 | 197 | 0.120 |
Why?
|
| Registries | 1 | 2019 | 778 | 0.120 |
Why?
|
| Anterior Cruciate Ligament Reconstruction | 1 | 2015 | 17 | 0.120 |
Why?
|
| Tensile Strength | 1 | 2014 | 80 | 0.120 |
Why?
|
| Gene Dosage | 3 | 2012 | 208 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 146 | 0.120 |
Why?
|
| Pericardial Effusion | 2 | 1993 | 20 | 0.120 |
Why?
|
| Prevalence | 2 | 2016 | 1240 | 0.120 |
Why?
|
| Videotape Recording | 1 | 2014 | 48 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2008 | 225 | 0.120 |
Why?
|
| Femur | 1 | 2015 | 111 | 0.120 |
Why?
|
| Arthroscopy | 1 | 2015 | 93 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 2 | 2014 | 576 | 0.120 |
Why?
|
| Thoracoscopes | 1 | 1993 | 2 | 0.120 |
Why?
|
| Remission Induction | 5 | 2011 | 740 | 0.120 |
Why?
|
| Mediastinal Cyst | 1 | 1993 | 3 | 0.110 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2016 | 178 | 0.110 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 1108 | 0.110 |
Why?
|
| Rabbits | 1 | 2014 | 638 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2015 | 1650 | 0.110 |
Why?
|
| Pleural Effusion | 2 | 1990 | 47 | 0.110 |
Why?
|
| Metaplasia | 2 | 2010 | 37 | 0.110 |
Why?
|
| Carcinoma, Large Cell | 1 | 2013 | 39 | 0.110 |
Why?
|
| Fistula | 1 | 1993 | 42 | 0.110 |
Why?
|
| Collagen | 1 | 2014 | 293 | 0.110 |
Why?
|
| Catheter Ablation | 2 | 2012 | 252 | 0.110 |
Why?
|
| Biomechanical Phenomena | 1 | 2014 | 473 | 0.110 |
Why?
|
| Focal Adhesions | 1 | 2013 | 70 | 0.110 |
Why?
|
| Mitochondrial Dynamics | 1 | 2013 | 56 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 2014 | 321 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1993 | 241 | 0.100 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2011 | 85 | 0.100 |
Why?
|
| Coronary Artery Disease | 1 | 2017 | 362 | 0.100 |
Why?
|
| Serotonin | 1 | 1993 | 221 | 0.100 |
Why?
|
| Mutation | 5 | 2016 | 4132 | 0.100 |
Why?
|
| Genetic Testing | 1 | 2016 | 537 | 0.100 |
Why?
|
| Quality Improvement | 1 | 2016 | 447 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 2362 | 0.100 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 643 | 0.100 |
Why?
|
| Preoperative Period | 1 | 2011 | 94 | 0.100 |
Why?
|
| Precision Medicine | 1 | 2016 | 410 | 0.100 |
Why?
|
| Patient Preference | 1 | 2012 | 108 | 0.100 |
Why?
|
| Global Health | 1 | 2013 | 186 | 0.100 |
Why?
|
| Cattle | 3 | 2000 | 375 | 0.100 |
Why?
|
| Leucovorin | 5 | 2020 | 224 | 0.100 |
Why?
|
| Cells, Cultured | 2 | 2014 | 2880 | 0.100 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.090 |
Why?
|
| Echocardiography | 2 | 2015 | 937 | 0.090 |
Why?
|
| Students, Medical | 1 | 2016 | 418 | 0.090 |
Why?
|
| Fluorouracil | 6 | 2020 | 561 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2015 | 475 | 0.090 |
Why?
|
| Diverticulum, Esophageal | 1 | 2010 | 6 | 0.090 |
Why?
|
| Arginine | 3 | 1996 | 138 | 0.090 |
Why?
|
| Heart Ventricles | 1 | 2015 | 779 | 0.090 |
Why?
|
| Disease Management | 1 | 2012 | 329 | 0.090 |
Why?
|
| Mucous Membrane | 1 | 2010 | 83 | 0.090 |
Why?
|
| Cause of Death | 2 | 2008 | 266 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 988 | 0.090 |
Why?
|
| Burns, Chemical | 2 | 1989 | 12 | 0.090 |
Why?
|
| Analysis of Variance | 3 | 2006 | 901 | 0.090 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 2009 | 8 | 0.090 |
Why?
|
| Logistic Models | 3 | 2016 | 1212 | 0.090 |
Why?
|
| Gastrostomy | 1 | 2010 | 69 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 1265 | 0.090 |
Why?
|
| ErbB Receptors | 2 | 2009 | 500 | 0.080 |
Why?
|
| Mood Disorders | 1 | 2009 | 81 | 0.080 |
Why?
|
| Lymphangiogenesis | 1 | 2008 | 39 | 0.080 |
Why?
|
| Mediastinal Neoplasms | 2 | 1989 | 47 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 2 | 2022 | 142 | 0.080 |
Why?
|
| Radiopharmaceuticals | 2 | 2022 | 193 | 0.080 |
Why?
|
| SRS-A | 1 | 1988 | 27 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2009 | 590 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 859 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 2 | 2012 | 1043 | 0.080 |
Why?
|
| DNA, Neoplasm | 1 | 2009 | 268 | 0.080 |
Why?
|
| Platelet Activating Factor | 1 | 1988 | 53 | 0.080 |
Why?
|
| Patient Admission | 1 | 2008 | 114 | 0.080 |
Why?
|
| Mice | 4 | 2015 | 11737 | 0.070 |
Why?
|
| Enzyme Inhibitors | 3 | 2009 | 645 | 0.070 |
Why?
|
| Vinblastine | 2 | 1998 | 108 | 0.070 |
Why?
|
| Signal Transduction | 2 | 2015 | 3373 | 0.070 |
Why?
|
| Cell Line, Tumor | 4 | 2015 | 2552 | 0.070 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 661 | 0.070 |
Why?
|
| Electroporation | 1 | 2006 | 57 | 0.070 |
Why?
|
| Odds Ratio | 1 | 2008 | 684 | 0.070 |
Why?
|
| Treatment Failure | 2 | 1997 | 287 | 0.070 |
Why?
|
| Comorbidity | 1 | 2009 | 948 | 0.060 |
Why?
|
| Neoplasm Grading | 2 | 2016 | 372 | 0.060 |
Why?
|
| Young Adult | 3 | 2016 | 6288 | 0.060 |
Why?
|
| Antineoplastic Agents | 5 | 2020 | 2411 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2008 | 395 | 0.060 |
Why?
|
| Genomics | 2 | 2023 | 761 | 0.060 |
Why?
|
| Ischemia | 1 | 2006 | 251 | 0.060 |
Why?
|
| Radiology, Interventional | 1 | 2024 | 69 | 0.060 |
Why?
|
| Databases, Bibliographic | 1 | 2003 | 17 | 0.060 |
Why?
|
| Genetic Therapy | 1 | 2006 | 370 | 0.060 |
Why?
|
| Central Venous Pressure | 1 | 2003 | 26 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2024 | 81 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1855 | 0.060 |
Why?
|
| Reoperation | 4 | 1996 | 598 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 84 | 0.050 |
Why?
|
| Canada | 1 | 2003 | 208 | 0.050 |
Why?
|
| Sepsis | 1 | 2006 | 319 | 0.050 |
Why?
|
| Recurrence | 2 | 1996 | 1140 | 0.050 |
Why?
|
| Publishing | 1 | 2003 | 90 | 0.050 |
Why?
|
| Research | 1 | 2003 | 252 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 1995 | 360 | 0.050 |
Why?
|
| Hydroxyurea | 4 | 1995 | 239 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 72 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 3 | 2009 | 921 | 0.050 |
Why?
|
| Biomarkers | 1 | 2008 | 1755 | 0.050 |
Why?
|
| Smoking | 2 | 2000 | 620 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 313 | 0.050 |
Why?
|
| Radiosurgery | 2 | 2016 | 280 | 0.050 |
Why?
|
| General Surgery | 1 | 2003 | 235 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2020 | 71 | 0.050 |
Why?
|
| Genotype | 2 | 2020 | 1848 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2008 | 277 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2015 | 1130 | 0.050 |
Why?
|
| Rheology | 1 | 2000 | 39 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2002 | 266 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1310 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 1796 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2003 | 575 | 0.040 |
Why?
|
| Chest Tubes | 1 | 2020 | 24 | 0.040 |
Why?
|
| Spinal Cord Compression | 1 | 1999 | 27 | 0.040 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 120 | 0.040 |
Why?
|
| Peritoneal Cavity | 2 | 1990 | 21 | 0.040 |
Why?
|
| Catheters, Indwelling | 1 | 2020 | 113 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 481 | 0.040 |
Why?
|
| Pressure | 1 | 2000 | 165 | 0.040 |
Why?
|
| Survivors | 1 | 2021 | 233 | 0.040 |
Why?
|
| Pulmonary Gas Exchange | 1 | 1999 | 32 | 0.040 |
Why?
|
| Radiotherapy | 2 | 2014 | 331 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2003 | 899 | 0.040 |
Why?
|
| Gallium Radioisotopes | 2 | 1989 | 31 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2003 | 1591 | 0.040 |
Why?
|
| Wounds, Penetrating | 1 | 1999 | 57 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 463 | 0.040 |
Why?
|
| Oxygen Consumption | 1 | 1999 | 243 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2015 | 1296 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 336 | 0.040 |
Why?
|
| Hospitals | 1 | 2020 | 299 | 0.040 |
Why?
|
| Esophagoscopes | 1 | 1997 | 3 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 1997 | 53 | 0.040 |
Why?
|
| Histamine Agonists | 1 | 1996 | 2 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 1996 | 13 | 0.040 |
Why?
|
| Rupture, Spontaneous | 1 | 1997 | 43 | 0.040 |
Why?
|
| Mass Screening | 1 | 2002 | 636 | 0.040 |
Why?
|
| Pulmonary Atelectasis | 1 | 1996 | 18 | 0.040 |
Why?
|
| DNA Primers | 2 | 2009 | 543 | 0.040 |
Why?
|
| Heartburn | 1 | 1996 | 10 | 0.030 |
Why?
|
| Endothelin Receptor Antagonists | 1 | 1996 | 11 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 1996 | 70 | 0.030 |
Why?
|
| Receptor, Endothelin A | 1 | 1996 | 21 | 0.030 |
Why?
|
| Hernia, Hiatal | 1 | 1997 | 38 | 0.030 |
Why?
|
| Electric Power Supplies | 1 | 1996 | 8 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1996 | 126 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2019 | 341 | 0.030 |
Why?
|
| Washington | 1 | 2015 | 49 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 1996 | 38 | 0.030 |
Why?
|
| Surgical Wound Dehiscence | 1 | 1996 | 37 | 0.030 |
Why?
|
| Pericardium | 2 | 1993 | 70 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 1999 | 373 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1996 | 96 | 0.030 |
Why?
|
| Emergencies | 1 | 1996 | 121 | 0.030 |
Why?
|
| Actuarial Analysis | 2 | 1993 | 66 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 3443 | 0.030 |
Why?
|
| Cervical Vertebrae | 1 | 1996 | 81 | 0.030 |
Why?
|
| Laparotomy | 1 | 1995 | 67 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 771 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 69 | 0.030 |
Why?
|
| Oligopeptides | 1 | 1996 | 188 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 35 | 0.030 |
Why?
|
| Piperidines | 1 | 1996 | 164 | 0.030 |
Why?
|
| Pain Management | 1 | 1996 | 137 | 0.030 |
Why?
|
| Ablation Techniques | 1 | 2015 | 36 | 0.030 |
Why?
|
| Deglutition Disorders | 1 | 1996 | 119 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2015 | 115 | 0.030 |
Why?
|
| Heterografts | 1 | 2015 | 102 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 195 | 0.030 |
Why?
|
| Watchful Waiting | 1 | 2015 | 63 | 0.030 |
Why?
|
| Dinoprost | 1 | 1994 | 26 | 0.030 |
Why?
|
| Muscle Relaxation | 1 | 1994 | 18 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 353 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 261 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 3 | 2008 | 270 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1995 | 166 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2023 | 2335 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2015 | 136 | 0.030 |
Why?
|
| Pericarditis, Constrictive | 1 | 1993 | 5 | 0.030 |
Why?
|
| Pericardiectomy | 1 | 1993 | 9 | 0.030 |
Why?
|
| Norepinephrine | 1 | 1994 | 170 | 0.030 |
Why?
|
| Intraoperative Complications | 1 | 1995 | 188 | 0.030 |
Why?
|
| Pain | 1 | 1996 | 400 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 1996 | 201 | 0.030 |
Why?
|
| Bone Neoplasms | 2 | 1993 | 329 | 0.030 |
Why?
|
| Chordoma | 1 | 1993 | 20 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2015 | 740 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 557 | 0.030 |
Why?
|
| Sacrum | 1 | 1993 | 43 | 0.030 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1993 | 126 | 0.030 |
Why?
|
| Scapula | 1 | 1993 | 24 | 0.030 |
Why?
|
| Forearm | 1 | 1993 | 31 | 0.030 |
Why?
|
| Perfusion | 1 | 1994 | 235 | 0.030 |
Why?
|
| Chondrosarcoma | 1 | 1993 | 48 | 0.030 |
Why?
|
| Staphylococcal Infections | 1 | 1996 | 269 | 0.030 |
Why?
|
| Heart Diseases | 1 | 2015 | 298 | 0.030 |
Why?
|
| Microbial Collagenase | 1 | 1992 | 3 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2012 | 127 | 0.030 |
Why?
|
| Histological Techniques | 1 | 1992 | 36 | 0.030 |
Why?
|
| Bradykinin | 1 | 1992 | 46 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2012 | 273 | 0.030 |
Why?
|
| Endothelium | 1 | 1992 | 58 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 1993 | 253 | 0.030 |
Why?
|
| Acetylcholine | 1 | 1992 | 177 | 0.020 |
Why?
|
| Computational Biology | 1 | 2015 | 542 | 0.020 |
Why?
|
| Curriculum | 1 | 2016 | 567 | 0.020 |
Why?
|
| Neutropenia | 3 | 1998 | 216 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.020 |
Why?
|
| Cell Movement | 1 | 2015 | 783 | 0.020 |
Why?
|
| Four-Dimensional Computed Tomography | 1 | 2011 | 19 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 2062 | 0.020 |
Why?
|
| Esophageal Motility Disorders | 1 | 1991 | 16 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 638 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 470 | 0.020 |
Why?
|
| Pericardial Window Techniques | 1 | 1990 | 1 | 0.020 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2011 | 58 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2015 | 595 | 0.020 |
Why?
|
| Rats | 2 | 2006 | 4040 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 1993 | 249 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 3027 | 0.020 |
Why?
|
| Veins | 1 | 1990 | 95 | 0.020 |
Why?
|
| DNA Methylation | 1 | 2015 | 657 | 0.020 |
Why?
|
| Taxoids | 1 | 2010 | 130 | 0.020 |
Why?
|
| Whole-Body Counting | 1 | 1989 | 7 | 0.020 |
Why?
|
| Semaphorins | 1 | 2009 | 17 | 0.020 |
Why?
|
| Heart Failure | 1 | 1999 | 1180 | 0.020 |
Why?
|
| Radiography, Thoracic | 2 | 1989 | 321 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1429 | 0.020 |
Why?
|
| Household Products | 1 | 1989 | 9 | 0.020 |
Why?
|
| Patient Compliance | 1 | 1990 | 230 | 0.020 |
Why?
|
| Pharynx | 1 | 1989 | 45 | 0.020 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2008 | 46 | 0.020 |
Why?
|
| Europe | 1 | 2009 | 321 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 77 | 0.020 |
Why?
|
| Larynx | 1 | 1989 | 38 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2009 | 280 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 2008 | 63 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 2439 | 0.020 |
Why?
|
| Genes, erbB-1 | 1 | 2008 | 16 | 0.020 |
Why?
|
| Mediastinoscopy | 1 | 1987 | 5 | 0.020 |
Why?
|
| Drug Administration Schedule | 3 | 1996 | 894 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 171 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 155 | 0.020 |
Why?
|
| Administration, Topical | 1 | 1988 | 96 | 0.020 |
Why?
|
| Age Distribution | 1 | 2008 | 200 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1988 | 312 | 0.020 |
Why?
|
| Sternum | 1 | 1987 | 34 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2009 | 529 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 451 | 0.020 |
Why?
|
| Steroids | 1 | 1989 | 174 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 229 | 0.020 |
Why?
|
| Piperazines | 1 | 2009 | 283 | 0.020 |
Why?
|
| Indoles | 1 | 2009 | 312 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 2008 | 308 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2007 | 31 | 0.020 |
Why?
|
| Colon | 2 | 1988 | 509 | 0.020 |
Why?
|
| Esophagitis | 2 | 1998 | 43 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2009 | 317 | 0.020 |
Why?
|
| Camptothecin | 1 | 2008 | 193 | 0.020 |
Why?
|
| Carboplatin | 1 | 2008 | 304 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2008 | 421 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2008 | 196 | 0.020 |
Why?
|
| RNA Interference | 1 | 2008 | 376 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2007 | 157 | 0.020 |
Why?
|
| Plasmids | 1 | 2006 | 291 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2008 | 479 | 0.020 |
Why?
|
| Base Sequence | 1 | 2009 | 2327 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 911 | 0.020 |
Why?
|
| Interferon-alpha | 2 | 1995 | 226 | 0.010 |
Why?
|
| Radiotherapy Dosage | 2 | 1998 | 470 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1940 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2006 | 1237 | 0.010 |
Why?
|
| Bibliometrics | 1 | 2003 | 37 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1989 | 786 | 0.010 |
Why?
|
| Skin | 1 | 2006 | 581 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1400 | 0.010 |
Why?
|
| Infant | 1 | 1989 | 3147 | 0.010 |
Why?
|
| Child, Preschool | 1 | 1989 | 3717 | 0.010 |
Why?
|
| Periodicals as Topic | 1 | 2003 | 168 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 3000 | 0.010 |
Why?
|
| Drug Evaluation | 2 | 1990 | 138 | 0.010 |
Why?
|
| Abdomen | 1 | 1997 | 122 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1996 | 64 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 1996 | 160 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1996 | 445 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1996 | 779 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1995 | 187 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 1997 | 461 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 1994 | 172 | 0.010 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1994 | 155 | 0.010 |
Why?
|
| Procarbazine | 1 | 1992 | 40 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1995 | 1012 | 0.010 |
Why?
|
| Immunologic Factors | 1 | 1994 | 171 | 0.010 |
Why?
|
| Methotrexate | 1 | 1992 | 250 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 1992 | 299 | 0.010 |
Why?
|
| Lymphedema | 1 | 1993 | 77 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1992 | 298 | 0.010 |
Why?
|
| Palliative Care | 1 | 1993 | 263 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1994 | 833 | 0.010 |
Why?
|
| Vindesine | 1 | 1989 | 9 | 0.010 |
Why?
|
| Laparoscopy | 1 | 1997 | 771 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1989 | 49 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1989 | 69 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 221 | 0.010 |
Why?
|
| Etoposide | 1 | 1989 | 198 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1990 | 682 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1994 | 1149 | 0.000 |
Why?
|
| Random Allocation | 1 | 1988 | 328 | 0.000 |
Why?
|
| Anastomosis, Surgical | 1 | 1988 | 273 | 0.000 |
Why?
|
| Radiography | 1 | 1988 | 809 | 0.000 |
Why?
|